Analysis of a volumetric-modulated arc therapy (VMAT) single phase prostate template as a class solution.

Related Articles

Analysis of a volumetric-modulated arc therapy (VMAT) single phase prostate template as a class solution.

Rep Pract Oncol Radiother. 2019 Jan-Feb;24(1):92-96

Authors: Hoffmann M, Pacey J, Goodworth J, Laszcyzk A, Ford R, Chick B, Greenham S, Westhuyzen J

Abstract
Aim: To assess a class solution template for volumetric-modulated arc therapy (VMAT) for prostate cancer using plan analysis software.
Background: VMAT is a development of intensity-modulated radiotherapy (IMRT) with potential advantages for the delivery of radiotherapy (RT) in prostate cancer. Class solutions are increasingly used for facilitating RT planning. Plan analysis software provides an objective tool for evaluating class solutions.
Materials and methods: The class solution for VMAT was based on the current static field IMRT template. The plans of 77 prostate cancer patients were evaluated using a set of in-house plan quality metrics (scores) (PlanIQ™, Sun Nuclear Corporation). The metrics compared the class solution for VMAT planning with the IMRT template and the delivered clinical plan (CP). Eight metrics were associated with target coverage and ten with organs-at-risk (OAR). Individual metrics were summed and the combined scores were subjected to non-parametric analysis. The low-dose wash for both static IMRT and VMAT plans were evaluated using 40 Gy and 25 Gy isodose volumes.
Results: VMAT plans were of equal or better quality than the IMRT template and CP for target coverage (combined score) and OAR combined score. The 40 Gy isodose volume was marginally higher with VMAT than IMRT (4.9%) but lower than CP (-6.6%)(P = 0.0074). The 25 Gy volume was significantly lower with VMAT than both IMRT (-32.7%) and CP (-34.4%)(P < 0.00001).
Conclusions: Automated VMAT planning for prostate cancer is feasible and the plans are equal to or better than the current IMRT class solution and the delivered clinical plan.

PMID: 30505239 [PubMed]

from PubMed via alexandrossfakianakis on Inoreader https://ift.tt/2QCTrWy